EarliTec Diagnostics, a medical device company, has successfully raised $21.5 million in a Series B financing round. This funding round was co-led by Nexus NeuroTech Ventures and Venture Investors Health Fund.

EarliTec Diagnostics aims to diagnose autism earlier in children. Research indicates that early diagnosis significantly improves developmental outcomes for children with autism.

The startup employs an FDA-authorized method that involves children as young as 16 months old watching short videos and social interactions on a screen.

During this 12-minute test, the device tracks the child’s eye movements using artificial intelligence (AI).

Children with autism exhibit different eye movement patterns compared to those without autism.

EarliTec’s technology is currently used by eight clinicians across six states in the U.S. Traditional autism assessments can take three to four hours and often have lengthy waitlists.

It's 12-minute test streamlines the diagnostic process, allowing clinicians to work with more children efficiently.

Autism-focused healthcare space has historically been challenging for fundraising.

However, there is growing momentum and interest from venture capitalists in this area.

The recent success of the Autism Impact Fund and other firms investing in neurodiversity-related solutions reflects this positive trend.